Traphaco Joint Stock Company (TRA) Fair Value & Analysis
Healthcare · VN · Market cap 3.3T VND
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 112,170 VND to 123,383 VND (+10.0%) since Jun 23, 2026. Share price +1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 62,593 VND – 78,385 VND · fair‑value band 73,102 VND – 165,631 VND · the 78,000 VND price screens below the 123,383 VND fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Traphaco Joint Stock Company (TRA) currently trades at 78,000 VND, while our model-based Fair Value estimate is 123,383 VND — implying the stock looks roughly 58.2% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Traphaco Joint Stock Company generated revenue of 2.7T VND at a net margin of 9.9%. Revenue grew 14.0% year over year. It earns a return on equity of 19.5%. The stock trades on a trailing P/E of 14.2. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Traphaco Joint Stock Company, together with its subsidiaries, produces and trades in pharmaceutical products, chemicals, and medical supplies and equipment in Vietnam. The company offers medical supplies; antipyretics; medicines for the hair, eyes, central neutral system, respiratory system, and liver; and other products. It is also involved in the production of medicines to treat human diseases, nutritional food products, and medicines derived from medicinal herbs; trading in medicines, pharmaceuticals, vaccines-biological products, chemicals, and nutritional food products; planting of medicinal materials; and processing of medicinal herbs. Further, it plants and processes pharmaceutical materials, and agriculture and forestry products, as well as food supplements, cosmetics, and chemicals. The company was formerly known as Pharmaceutical and Medical Material and Equipments Joint Stock Company and changed its name to Traphaco Joint Stock Company in July 2001. Traphaco Joint Stock C…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Traphaco Joint Stock Company reported revenue of 2.7T VND in FY2025 versus 2.2T VND in FY2021, a compound +5.3%/yr. Reported net income was 250B VND in FY2025, compounding +0.8%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,747 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Traphaco Joint Stock Company (TRA) undervalued?
What is the fair value of TRA?
What is the quality score of TRA?
What is the revenue of Traphaco Joint Stock Company (TRA)?
What is the net profit margin of TRA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.